article thumbnail

Illingworth: mobile nursing can reduce trial patient burden

Outsourcing Pharma

A leader from home-based clinical services firm Illingworth Research Group talks about the evolution of mobile nursing and how it can keep trials going.

Nurses 94
article thumbnail

Finding the right partners key to decentralized trials: Illingworth

Outsourcing Pharma

A leader from the mobile research nursing specialist offers advice on what to look for in a service provider, and why finding the right one is vital.

Nurses 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Benefits of Working for a Rapidly Growing Global Clinical Research Organization (CRO) like Medpace

XTalks

A clinical research organization (CRO) is a company that delivers outsourced services to plan, manage and execute clinical trials for biotechnology, pharmaceutical, and medical device companies. Medpace has various opportunities for nurses and other healthcare professionals.

article thumbnail

?5 Things You Need to Know from Our Recent Gene Therapy Webinar

Worldwide Clinical Trials

We’ve also seen a decrease in available research nurses, as they have had to be reassigned to COVID patients. It really is—there has been a 10x increase in cell and gene therapies in the clinical development pipeline since 2012. Fewer staff creates many problems, including less bandwidth to meet for reviews and approvals.

article thumbnail

World Parkinson’s Day 2023 and Promising Parkinson’s Disease Treatments

XTalks

ND0612 is currently in Phase III of clinical development and is supported by four years of safety data. Promising Treatments for Parkinson’s Disease Although there is currently no cure for Parkinson’s disease, there are combinations of medications, surgical treatments and other therapies that can relieve symptoms in patients.

article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Side effects and cost implications. Professional reception of the findings.

article thumbnail

“Nothing scares us” – Ukraine’s clinical research sector begins fearless recovery

Drug Discovery World

The drop in recruiting sites in Ukraine and in Russia sadly confirms our earlier prediction that the impact of war in the region on clinical development, and most importantly on patients, is considerable. For more on the industry’s response to the conflict, read the DDW article ‘ The Ukraine Conflict – The challenge for Pharma ’. .